Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
Yun‐Gyoo Lee, Hyun Chang, Bhumsuk Keam, et al.
Cancer Research and Treatment (2020) Vol. 53, Iss. 3, pp. 671-677
Open Access | Times Cited: 24

Showing 24 citing articles:

Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis
Yukinori Takenaka, Ryohei Oya, Norihiko Takemoto, et al.
Head & Neck (2022) Vol. 44, Iss. 5, pp. 1237-1245
Closed Access | Times Cited: 45
Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols
Catherine T. Haring, Lulia A. Kana, Sarah M. Dermody, et al.
Cancer (2023) Vol. 129, Iss. 18, pp. 2817-2827
Open Access | Times Cited: 36
Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis
Jialin Su, Li Yu-ning, Shuhua Tan, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma
Piero Giuseppe Meliante, Federica Zoccali, Marco de Vincentiis, et al.
Diagnostics (2023) Vol. 13, Iss. 5, pp. 862-862
Open Access | Times Cited: 17
A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors
Dengxiong Kang, Siping Liu, Xin Yuan, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 20, pp. 18215-18240
Open Access | Times Cited: 12
Characterization of macrophages in head and neck squamous cell carcinoma and development of MRG-based risk signature
Lei Liu, Qiang Liu
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis
María A. López-Olivo, Valeria Valerio, Aliza R. Karpes Matusevich, et al.
Vaccines (2022) Vol. 10, Iss. 8, pp. 1195-1195
Open Access | Times Cited: 18
Risk Factors for Progressive Disease After Immune Checkpoint Inhibitor Therapy in Head and Neck Squamous Cell Carcinoma
Seo Yoon Jang, Yun‐Gyoo Lee, Sang Hoon Chun, et al.
Head & Neck (2025)
Closed Access
Neutrophil‐to‐Lymphocyte Ratio as a Predictor for PD‐L1 Inhibitor Treatment in Recurrent or Metastatic Nasopharyngeal Carcinoma
Kun Gao, Zhigong Wei, Zheran Liu, et al.
Head & Neck (2025)
Closed Access
Exploring Surgical Oncology-Based Comparative and Systematic Analysis of the Diagnostic Potential of Various Novel Biomarkers in Head and Neck Squamous Cell Carcinoma
Mostafa Ahmed Abdellah Ahmed, Amna Batool, Ali Rababah, et al.
Cureus (2025)
Open Access
Neutrophil/lymphocyte ratio: a potential biomarker in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors
Marianna Caterino, Giorgio Lo Giudice, Vincenzo Damiano, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as potential predictive markers of treatment response in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Tibera K. Rugambwa, Omar Ahmed, Xiangyang Zhang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 9
Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study
Dong Hyun Kim, Seung Taek Lim, Hye Ryun Kim, et al.
Oral Oncology (2024) Vol. 151, pp. 106739-106739
Closed Access | Times Cited: 3
Integrating Cutting-Edge Methods to Oral Cancer Screening, Analysis, and Prognosis
Sagar Dholariya, Ragini Singh, Amit Sonagra, et al.
Critical Reviews™ in Oncogenesis (2023) Vol. 28, Iss. 2, pp. 11-44
Closed Access | Times Cited: 7
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival
Khalil Choucair, Caroline A. Nebhan, Alessio Cortellini, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5052-5052
Open Access | Times Cited: 7
Predictive value of early dynamic changes of NLR and PLR for the efficacy of immune checkpoint inhibitor in head and neck squamous cell carcinoma
Dong Hyun Kim, Seo Yoon Jang, Bhumsuk Keam
Oral Surgery Oral Medicine Oral Pathology and Oral Radiology (2024) Vol. 138, Iss. 6, pp. 763-771
Closed Access | Times Cited: 2
Neutrophil‐to‐Lymphocyte Ratio and Pembrolizumab Outcomes in Oral Cavity Squamous Cell Carcinoma
Angeline Truong, Rex H. Lee, Xin Wu, et al.
Otolaryngology (2024)
Closed Access | Times Cited: 2
Identification of Immune-Related LncRNA Pairs for Predicting Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma
Xueying Wang, Kui Cao, Erliang Guo, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 14
Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review
Camil Ciprian Mireștean, Mihai Cosmin Stan, Michael Schenker, et al.
Diagnostics (2023) Vol. 13, Iss. 16, pp. 2620-2620
Open Access | Times Cited: 5
Roles of Major RNA Adenosine Modifications in Head and Neck Squamous Cell Carcinoma
Xingxing Huo, Shujie Wang, Hang Song, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 6
Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers: The Early Experience of Two Academic Center
Camil Ciprian Mireștean, Mihai Cosmin Stan, Michael Schenker, et al.
(2023)
Open Access | Times Cited: 2
Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients
Junliang Li, Tsai-Ling Hsieh, Ming-Che Ou, et al.
Oral Oncology (2022) Vol. 126, pp. 105729-105729
Closed Access | Times Cited: 3
Inflammatory markers as prognostic markers in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Quan Wang, Xiangzhi Yin, S. Wang, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors
D. Kang, S. Liu, Xin Yuan, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top